InvestorsHub Logo
Followers 62
Posts 7554
Boards Moderated 1
Alias Born 01/02/2003

Re: None

Saturday, 02/04/2023 6:37:57 AM

Saturday, February 04, 2023 6:37:57 AM

Post# of 426363
Amarin's main problem in the U.S. is EXCLUSIVITY LOSS for Vascepa...The best way to deal with this is to regain U.S. patent protection by marketing patented MND-2119 products...
Amarin's main problem in Europe is PRICE PUSHBACK on Vaskepa...The best way to deal with this is to regain markets by charging national health care systems for licenses in return for charging less for Vaskepa.

The end goal should be to make EPA products available globally for all adults.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News